 |
||||
 |
CBio was established in 2000
to develop and commercialise treatments for autoimmune diseases.
In 2001, extended preclinical studies at the University of Queensland
concluded that a heat shock protein identified as chaperonin 10
played a key role in down-regulating the innate immune response
in patients during pregnancy. Further research suggested that
chaperonin 10 appeared to intercede at a very early stage
of the inflammatory process to prevent the over-expression of
pro-inflammatory cytokines. Based on this research, CBio acquired
a worldwide exclusive licence for the chaperonin 10 intellectual
property, and now has clinical data and a robust IP portfolio
surrounding the technology. |
 |
|
|
